Spots Global Cancer Trial Database for Post-Marketing Surveillance Study of OTEZLA
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Post-Marketing Surveillance Study of OTEZLA
Official Title: OTEZLA® Tablets Drug Use-Results Survey
Study ID: NCT03284879
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tugi dermatology clinic, Kitakyushu, Fukuoka, Japan
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
